Floatz logo

ct-868

Overweight

Carmot Therapeutics, Inc.Phase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
65/ 100

Competitive context

574 Active assets in the Overweight cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB

View all 50 →

Same molecule, other indications

ct-868 is also rated in:

type 1 diabetes mellitusDormant
BB
Indicative ·
64 / 100
View asset →
obesity disorderDormant
B
Indicative ·
62 / 100
View asset →
type 2 diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →